$37.60
+0.55 (+1.48%)
Open$37.12
Previous Close$37.05
Day High$38.28
Day Low$37.03
52W High$47.84
52W Low$3.43
Volume—
Avg Volume791.8K
Market Cap2.26B
P/E Ratio—
EPS$-4.17
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
-66.0% upside
Current
$37.60
$37.60
Target
$12.80
$12.80
$8.80
$12.80 avg
$18.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 639.02M | 671.15M | 526.83M |
| Net Income | 3.07M | 3.06M | 2.31M |
| Profit Margin | 0.5% | 0.5% | 0.4% |
| EBITDA | 3.98M | 4.67M | 3.27M |
| Free Cash Flow | 2.86M | 3.84M | 2.49M |
| Rev Growth | +2.1% | +18.5% | -6.0% |
| Debt/Equity | 0.55 | 0.45 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |